Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis – evidence summary (ED35)
This evidence summary focuses on the license extension for Crohn's disease and ulcerative colitis. Remsima (SC) can be self-administered at home if the person, family member or carer is given appropriate training, unlike intravenous infliximab, which is given in secondary care.
Source:
National Institute for Health and Care Excellence